Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

News

FDA Approves Pembrolizumab as Adjuvant Therapy for NSCLC

Medical Literature

The Role of Postoperative Intensity-Modulated Radiation Therapy for Incompletely Resected NSCLC

Medical Literature

How Oncogene-Driven Lung Cancer May Impact Pregnancy and Motherhood

Medical Literature

5-Year Follow-up of KEYNOTE-042: Pembrolizumab Versus Chemotherapy in NSCLC

News

Adding a Novel Antibody to Anti–PD-1 Immunotherapy for Metastatic NSCLC

News

Radiation and Immunotherapy Given Together May Be of Benefit for Some Patients With Lung Cancer

Medical Literature

CT-Based Versus Minimal Follow-up for Patients With Resected NSCLC: Difference in Survival?

Mirek Fatyga, PhD, on Radiation Therapy and Cardiac Toxicities When Treating NSCLC

Qinjin Fan, PhD, on Mortgage Discrimination and a Potential Link to Less Guideline-Concordant Care in Lung Cancer

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

(UPDATE) Pembrolizumab (Keytruda) in NSCLC

(UPDATE) Nivolumab (Opdivo) in NSCLC

(UPDATE) Afatinib (Gilotrif)

Sotorasib

View More

More

News

FDA Brief: Accelerated Approval Granted for Adagrasib in KRAS G12C–Mutated Lung Cancer

FDA Approves Pembrolizumab as Adjuvant Therapy for NSCLC

SITC 2022: Can ctDNA Help to Predict Therapeutic Outcomes in Patients With NSCLC?

Impact of Low-Dose CT Screening on Lung Cancer Incidence and Stage Migration

Can Weight Gain Improve Clinical Outcomes for Patients With Advanced NSCLC?

ASTRO 2022: Phase III Trial Compares Radiotherapy Regimens for Early-Stage NSCLC

Neoadjuvant Atezolizumab: Focus of National Study in Resectable NSCLC

Neoadjuvant Use of Ipilimumab Plus Nivolumab and Chemoradiotherapy for NSCLC

View More

Advertisement

Published

Medical Literature

Adjuvant Atezolizumab Versus Best Supportive Care in Resected Early-Stage NSCLC: IMpower010 Results

Use of Nintedanib/Docetaxel in Advanced Nonsquamous Lung Cancer: Phase III Trial Results

Update From ALTER-L004: First-Line Anlotinib Plus Icotinib in EGFR-Mutated NSCLC

Does Bias Affect Overall Survival Reporting in ALK-Positive NSCLC Treated With Alectinib Versus Ceritinib?

View More

Ongoing

CE Activities

Tailoring Targeted Therapy: New Directions for Managing Patients Across the Spectrum of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer: Management of Patients With Resectable Disease

Meet The Professor: Current and Future Role of Immunotherapy in the Management of Lung Cancer — Part 1 of a 4-Part Series

ALK- or ROS1-Rearranged NSCLC: Effectively Integrating Precision Medicine into Patient-Centered Care

View More

Available

Clinical Trials

The University of Texas MD Anderson Cancer Center, NORTHSTAR Trial

Fox Chase Cancer Center

City of Hope Comprehensive Cancer Center

A Randomized Phase II Trial of Adjuvant Pembrolizumab for Stage I Non-Small Cell Lung Cancer with Primary Tumors Between 1-4 cm

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.